Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with recombinant somatropin: German collaborative study.

J R Bierich1

  • 1Department of Paediatrics, University of Tübingen, West Germany.

Acta Paediatrica Scandinavica. Supplement
|January 1, 1988
PubMed
Summary

Recombinant somatropin significantly improved height velocity in children with growth hormone deficiency. This treatment demonstrated good tolerance and no adverse antibody development in a multicentre trial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constitutional delay of growth and adolescence. Results of short-term and long-term treatment with GH.

Acta endocrinologica·1992
Same author

Aetiology and pathogenesis of growth hormone deficiency.

Bailliere's clinical endocrinology and metabolism·1992
Same author

Constitutional delay of growth and adolescence.

Bailliere's clinical endocrinology and metabolism·1992
Same author

[The treatment of aging subjects with growth hormone].

Zeitschrift fur Gerontologie·1991
Same author

New observations on midline defects: coincidence of anophthalmos, microphthalmos and cryptophthalmos with hypothalamic disorders.

European journal of pediatrics·1991
Same author

[Growth hormone profile in constitutional and acquired developmental delay].

Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde·1990

Area of Science:

  • Pediatric Endocrinology
  • Biotechnology
  • Clinical Trials

Background:

  • Growth hormone deficiency (GHD) impacts child development.
  • Traditional pituitary-derived growth hormone (GH) has limitations.
  • Recombinant DNA technology offers an alternative GH source.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant somatropin in GHD patients.
  • To compare treatment outcomes in previously untreated and previously GH-treated patients.

Main Methods:

  • A multicentre trial involving 62 GHD patients in West Germany.
  • Patients received recombinant somatropin (12 IU/m2/week) subcutaneously for at least 12 months.
  • Height velocity was measured before and during treatment.

Related Experiment Videos

Main Results:

  • Height velocity increased from 3.4 cm/year to 10.4 cm/year in previously untreated patients.
  • Height velocity increased from 6.0 cm/year to 8.3 cm/year in previously GH-treated patients.
  • Recombinant somatropin was well-tolerated with no anti-GH antibodies detected.

Conclusions:

  • Recombinant somatropin is an effective treatment for GHD.
  • The treatment shows significant growth promotion in both treatment-naive and previously treated GHD populations.
  • Recombinant somatropin is safe and immunologically well-tolerated.